Marc Vandemeulebroecke

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Topics

Hidradenitis Suppurativa

Top Venues

Clinical trials (London, England)

Pharmaceutical statistics

This page only lists publications with an associated author ORCID identifier.

Publications

Marc Vandemeulebroecke, Dieter A Häring, Eva Hua, Xiaoling Wei, Dong Xi
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials. Clinical trials (London, England) (2024)
Marc Vandemeulebroecke, Dieter A Häring, Eva Hua, Xiaoling Wei, Dong Xi
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials. Clinical trials (London, England) 21 (2) (2024)
Anna Passera, Elisa Muscianisi, David Demanse, Ginette A Okoye, Gregor B E Jemec, Tiffany Mayo, Jennifer Hsiao, Vivian Y Shi, Angel S Byrd, Xiaoling Wei, Lorenz Uhlmann, Marc Vandemeulebroecke, Shoba Ravichandran, Martina L Porter
New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials. Journal of the European Academy of Dermatology and Venereology : JEADV (2024)
Marc Vandemeulebroecke, Dieter A Häring, Eva Hua, Xiaoling Wei, Dong Xi
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials. Clinical trials (London, England) 21 (2) (2024)
Marc Vandemeulebroecke, Dieter A Häring, Eva Hua, Xiaoling Wei, Dong Xi
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials. Clinical trials (London, England) 21 (2) (2024)
Marc Vandemeulebroecke, Dieter A Häring, Eva Hua, Xiaoling Wei, Dong Xi
New strategies for confirmatory testing of secondary hypotheses on combined data from multiple trials. Clinical trials (London, England) (2024)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Mathias Cardner, Danny Tuckwell, Anna Kostikova, Pascal Forrer, Richard M Siegel, Alain Marti, Marc Vandemeulebroecke, Enrico Ferrero
Analysis of serum proteomics data identifies a quantitative association between beta-defensin 2 at baseline and clinical response to IL-17 blockade in psoriatic arthritis. RMD open 9 (2) (2023)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Marc Vandemeulebroecke, Mark Baillie, Ardalan Mirshani, Emmanuel Lesaffre
DMC reports in the 21st century: towards better tools for decision-making. Trials 24 (1) (2023)
Marc Vandemeulebroecke, Mark Baillie, David Carr, Linda Kanitra, Alison Margolskee, Andrew Wright, Baldur Magnusson
How can we make better graphs? An initiative to increase the graphical expertise and productivity of quantitative scientists. Pharmaceutical statistics 18 (1) (2018)